Bristol-Myers Excedrin sales up 10% to $55 mil. in third quarter; Boost sales are $19 mil..
This article was originally published in The Tan Sheet
Executive Summary
BRISTOL-MYERS EXCEDRIN SALES UP 10% TO $55 MIL. IN THIRD QUARTER, helping the company's consumer products revenues rise 4% during the three-month period, Bristol-Myers Squibb reported Oct. 21. Consumer products revenues rose 11% excluding the negative effect of foreign currency translations versus the strong dollar, the company said. Excedrin received a recommendation for approval as an OTC treatment for migraine by an FDA advisory committee in July, the company noted. The product line also likely continues to benefit from the recommendations for low-dose aspirin use in the primary and secondary prevention of cardiovascular disease.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning